Platinum Therapy Should Not Be Delayed in Ovarian Cancer Relapse

Share this content:
Researchers examined the differences in outcomes in patients with ovarian cancer who received platinum-based chemotherapy and non-platinum based chemotherapy after relapse.
Researchers examined the differences in outcomes in patients with ovarian cancer who received platinum-based chemotherapy and non-platinum based chemotherapy after relapse.

Platinum-based chemotherapy (PBC) should not be delayed in favor of non-platinum-based therapy (NPBC) in patients with partially platinum-sensitive ovarian cancer (OC), according to a study published in the Journal of Clinical Oncology.1

Many patients with OC who undergo primary surgery and respond to PBC eventually experience relapse and disease progression. There is evidence that shows that the efficacy of subsequent PBC increases with a longer platinum-free interval (PFI), and administering NPBC to prolong the PFI may improve outcomes.

The phase 3 MITO-8 study (ClinicalTrials.gov Identifier: NCT00657878) randomly assigned 215 patients with partially platinum-sensitive OC who experienced disease progression 6 to 12 months after their last platinum therapy to the standard arm or experimental arm.  Patients in the standard arm received PBC at current relapse and NPBC at subsequent relapse, and patients in the experimental arm received NPBC at current relapse and PBC at subsequent relapse.

Patients in the experimental arm experienced a significantly prolonged PFI from random assignment (7.8 months vs 0.01 months) and from last platinum injection prior to enrollment into the study (median 15.8 months vs 8 months).

The median overall survival (OS) was 21.8 months (95% CI, 16.3-29.3) in the experimental arm vs 24.5 months (95% CI, 22.41-33.6) in the standard arm (P = .83), demonstrating no benefit for OS.

Patients in the experimental arm had a significantly shorter progression-free survival with median 12.8 months vs 16.4 months for the standard arm (hazard ratio, 1.41; 95% CI, 1.04-1.92; P = .025). 

RELATED: Additional FDA Approval for Olaparib Tablets in Ovarian Cancer

The study ended prematurely due to slow enrollment.

The authors concluded by stating platinum rechallenge should “not be delayed in favor of nonplatinum treatment in patients with partially platinum-sensitive OC.”

Reference

  1. Pignata S, Scambia G, Bologna A, et al. Randomized controlled trial testing the efficacy of platinum-free interval prolongation in advanced ovarian cancer: the MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study. J Clin Oncol. 2017 Aug 21. doi: 10.1200/JCO.2017.73.4293 

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters